top of page
Search
Writer's pictureThe Halo Team

Vanquish Bio partners with Saint Louis University

Updated: Jun 30, 2021

ST. LOUIS, MO, ORLANDO, FL, JUNE 10, 2021 -- Recently, Vanquish Bio LLC, a biotechnology company researching the development of Natural Killer (NK) cell line-derived extracellular vesicles (EVs), entered into a collaboration with Saint Louis University (SLU).


This past April, Vanquish submitted a grant to the National Institutes of Health through the Small Business Technology Transfer (STTR) program. The grant seeks funding to further their research for the development of NK-derived EVs as a new treatment for cancer.


Dr. Jacki Kornbluth serves as Chief Scientific Officer and is a Professor of Pathology at the Saint Louis University (SLU) School of Medicine.

The partnership between Vanquish and SLU is ideally suited for this purpose because Dr. Kornbluth’s laboratory at SLU has been studying the anti-tumor effects of NK cell lines for more than three decades.


We have preliminary evidence that NK extracellular vesicles kill cancer stem cells,” Dr. Kornbluth said. “Cancer cells evade standard treatment and are responsible for metastasis and recurrence. NK EVs also kill tumor cells that become resistant to front-line chemotherapy.”


The studies proposed in the grant application will generate pre-clinical data which will lead to an additional treatment for myeloma. Multiple myeloma represents approximately 10% of all hematological cancers resulting in approximately 32,110 new cases and 12,960 deaths per year.

349 views0 comments

Recent Posts

See All

Comentarios


bottom of page